Daiichi Sankyo reorganizes R&D in India
Daiichi Sankyo Company, Limited has announced its decision to close its research subsidiary, Daiichi Sankyo India Pharma Private Limited, to increase R&D productivity.
Daiichi Sankyo is reviewing its global R&D system with the aim of decreasing R&D operations costs and redistributing resources to the further development of its R&D pipeline.
DSIN presently employs approximately 170 people, mainly engaged in conducting drug discovery research targeting infectious diseases and inflammation. Following its closure, the DSIN R&D pipeline (including research themes selected by the Global Health Innovative Technology Fund [GHIT Fund]) will be transferred to Daiichi Sankyo’s R&D Division.